PLS-123

CAT: 0804-HY-120406Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-120406Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
LPS-123 is a covalently irreversible BTK inhibitor with an IC50 of AKT/mTOR and MAPK signaling pathways, activation of PLCγ2, ERK1/2, p38, AKT, and mTOR, and blocks the production of CCL3 and CCL4 chemokines. LPS-123 exhibits significant anti-proliferative activity against various B-cell lymphoma cell lines and effectively induces apoptosis via a caspase-dependent pathway. LPS-123 also demonstrates significant antitumor activity in the OCI-Ly7 xenograft model. LPS-123 can be used for lymphoma research[1].
CAS Number
[1431727-04-6]
UNSPSC
12352005
Target
Akt; Apoptosis; Btk; CCR; ERK; mTOR; p38 MAPK
Related Pathways
Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=C(NC1=CN=C(NC2=CC=CC(NC(CNC(C=C)=O)=O)=C2)N=C1)C3=CC(NC(C4=CC=CC(C(F)(F)F)=C4)=O)=CC=C3C
Molecular Formula
C31H26F3N7O4
Molecular Weight
617.58
References & Citations
[1]Ding N, et al. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. Oncotarget. 2015 Jun 20;6 (17) :15122-36.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products